The round was led by S2G Ventures, bringing total funding to date to $67 million. The proceeds of the financing will be used to advance Faeth's clinical trials that combine nutrient control, therapeutics and digital tools to inhibit cancer metabolism. Seed round co-lead investors Khosla Ventures and Future Ventures also participated in the Series A, along with additional support from Digitalis, KdT Ventures, AgFunder, and Cantos.

Faeth Therapeutics is a cancer metabolism company developing clinically-tested nutrition control, therapeutics, and digital tools for the treatment of cancer. Founded in 2019 by leading researchers in Europe and the United States and backed by leading investors, the company is pioneering its work in cancer metabolism to support a radically new way to treat cancer. Faeth's research, published in peer-reviewed scientific journals, shows that tailoring the right diet to the cancer patient can significantly impact the efficacy of clinically tested therapeutics for cancer. Feed the fight.